JP2010529143A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010529143A5 JP2010529143A5 JP2010511387A JP2010511387A JP2010529143A5 JP 2010529143 A5 JP2010529143 A5 JP 2010529143A5 JP 2010511387 A JP2010511387 A JP 2010511387A JP 2010511387 A JP2010511387 A JP 2010511387A JP 2010529143 A5 JP2010529143 A5 JP 2010529143A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- tautomer
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 45
- 150000003839 salts Chemical class 0.000 claims 38
- 125000003118 aryl group Chemical group 0.000 claims 26
- 239000000203 mixture Substances 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000001153 fluoro group Chemical group F* 0.000 claims 10
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 10
- 241001465754 Metazoa Species 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 230000015654 memory Effects 0.000 claims 3
- 208000020016 psychiatric disease Diseases 0.000 claims 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- -1 -NR a R b Chemical group 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000007787 long-term memory Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000006403 short-term memory Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 0 CN(C*)*CNI Chemical compound CN(C*)*CNI 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94300507P | 2007-06-08 | 2007-06-08 | |
| PCT/US2008/066201 WO2008154438A1 (en) | 2007-06-08 | 2008-06-06 | Therapeutic pyrazoloquinoline derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010529143A JP2010529143A (ja) | 2010-08-26 |
| JP2010529143A5 true JP2010529143A5 (enExample) | 2011-07-14 |
Family
ID=40096440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010511387A Pending JP2010529143A (ja) | 2007-06-08 | 2008-06-06 | 治療用ピラゾロキノリン誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7872002B2 (enExample) |
| EP (1) | EP2166852B1 (enExample) |
| JP (1) | JP2010529143A (enExample) |
| KR (1) | KR20100039331A (enExample) |
| CN (1) | CN101742908A (enExample) |
| AT (1) | ATE544344T1 (enExample) |
| AU (1) | AU2008261884A1 (enExample) |
| BR (1) | BRPI0812366A2 (enExample) |
| CA (1) | CA2688395A1 (enExample) |
| ES (1) | ES2386168T3 (enExample) |
| IL (1) | IL202270A0 (enExample) |
| MX (1) | MX2009013202A (enExample) |
| WO (1) | WO2008154438A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2483728T3 (es) * | 2007-06-08 | 2014-08-07 | Dart Neuroscience (Cayman) Ltd | Derivados terapéuticos de pirazolonafatiridina |
| ES2386168T3 (es) * | 2007-06-08 | 2012-08-10 | Helicon Therapeutics, Inc. | Derivados de pirazoloquinolina terapéuticos |
| US7863266B2 (en) * | 2007-06-08 | 2011-01-04 | Helicon Therapeutics, Inc. | Therapeutic pyrazoloquinoline urea derivatives |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| WO2017085053A1 (en) | 2015-11-16 | 2017-05-26 | Fundación Para La Investigación Médica Aplicada | Novel compounds as inhibitors of dna methyltransferases |
| CN105294648B (zh) * | 2015-11-30 | 2017-11-28 | 山东罗欣药业集团股份有限公司 | 一种西他沙星的制备方法 |
| CN116390923B (zh) * | 2020-08-21 | 2025-08-29 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3204126A1 (de) * | 1982-02-06 | 1983-08-11 | Bayer Ag, 5090 Leverkusen | Pyrazoloxazine, -thiazine, -chinoline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US4814450A (en) | 1984-07-09 | 1989-03-21 | Ciba-Geigy Corporation | Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives |
| JPS61112075A (ja) * | 1984-11-05 | 1986-05-30 | Shionogi & Co Ltd | チエニルピラゾロキノリン誘導体 |
| EP0214092A1 (en) | 1985-08-08 | 1987-03-11 | Ciba-Geigy Ag | Enhanced absorption of psychoactive 2-aryl-pyrazolo quinolines as a solid molecular dispersion in polyvinylpyrrolidone |
| US5334595A (en) * | 1992-10-23 | 1994-08-02 | Sterling Winthrop Inc. | Pyrazoloquinolones as anticancer agents |
| GB9716347D0 (en) * | 1997-08-01 | 1997-10-08 | Merck Sharp & Dohme | Therapeutic compounds |
| TWI271406B (en) | 1999-12-13 | 2007-01-21 | Eisai Co Ltd | Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same |
| GB0108475D0 (en) * | 2001-04-04 | 2001-05-23 | Merck Sharp & Dohme | New compounds |
| JP3896309B2 (ja) * | 2001-07-09 | 2007-03-22 | ファイザー株式会社 | プロテインキナーゼｃ阻害物質としてのピラゾロキノリノン誘導体 |
| ATE425164T1 (de) | 2002-12-16 | 2009-03-15 | Active Biotech Ab | Tetrazyklische immunmodulierende verbindungen |
| AR045689A1 (es) | 2003-05-29 | 2005-11-09 | Millennium Pharm Inc | Compuestos derivados de 2,5-dihidro-pirazolo[4,3-c]quinolin-4-ona como inhibidores de chk-1 y composiciones farmaceuticas que los contienen |
| US7544697B2 (en) | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
| AU2006287378A1 (en) | 2005-09-07 | 2007-03-15 | Braincells, Inc. | Modulation of neurogenesis by HDac inhibition |
| JP2008047893A (ja) * | 2006-08-11 | 2008-02-28 | Samsung Electronics Co Ltd | 薄膜トランジスタ表示板及びその製造方法 |
| ES2386168T3 (es) * | 2007-06-08 | 2012-08-10 | Helicon Therapeutics, Inc. | Derivados de pirazoloquinolina terapéuticos |
-
2008
- 2008-06-06 ES ES08770402T patent/ES2386168T3/es active Active
- 2008-06-06 KR KR1020107000330A patent/KR20100039331A/ko not_active Withdrawn
- 2008-06-06 CN CN200880024823A patent/CN101742908A/zh active Pending
- 2008-06-06 US US12/135,036 patent/US7872002B2/en not_active Expired - Fee Related
- 2008-06-06 EP EP08770402A patent/EP2166852B1/en not_active Not-in-force
- 2008-06-06 MX MX2009013202A patent/MX2009013202A/es active IP Right Grant
- 2008-06-06 AT AT08770402T patent/ATE544344T1/de active
- 2008-06-06 CA CA002688395A patent/CA2688395A1/en not_active Abandoned
- 2008-06-06 AU AU2008261884A patent/AU2008261884A1/en not_active Abandoned
- 2008-06-06 BR BRPI0812366A patent/BRPI0812366A2/pt not_active IP Right Cessation
- 2008-06-06 WO PCT/US2008/066201 patent/WO2008154438A1/en not_active Ceased
- 2008-06-06 JP JP2010511387A patent/JP2010529143A/ja active Pending
-
2009
- 2009-11-22 IL IL202270A patent/IL202270A0/en unknown
-
2010
- 2010-11-18 US US12/949,655 patent/US8598159B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010529143A5 (enExample) | ||
| HRP20151250T1 (hr) | Derivati izoksazolo-piridina | |
| JP2013501720A5 (enExample) | ||
| JP2010504286A5 (enExample) | ||
| PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
| PE20140623A1 (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
| PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
| PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
| PE20081612A1 (es) | Analogos de las pterinas | |
| JP2017509689A5 (enExample) | ||
| JP2012041349A5 (enExample) | ||
| JP2008513498A5 (enExample) | ||
| PE20121614A1 (es) | Derivados de 6-amino,4-carbonil-pirimidina sustituida como antagonistas del receptor ccr2 | |
| HRP20171028T1 (hr) | Indolski i indazolski spojevi koji aktiviraju ampk | |
| JP2013519684A5 (enExample) | ||
| PE20110063A1 (es) | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK | |
| JP2011006480A5 (enExample) | ||
| PE20140703A1 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
| PE20091819A1 (es) | DERIVADOS POLISUSTITUIDOS DE 2-HETEROARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLIACION EN TERAPEUTICA | |
| PE20080772A1 (es) | Nuevos derivados de bipiridina sustituidos y su uso | |
| PE20130576A1 (es) | Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10 | |
| JP2009533343A5 (enExample) | ||
| JP2016501185A5 (enExample) | ||
| JP2010529144A5 (enExample) | ||
| JP2012097115A5 (enExample) |